Act1 is an essential adaptor in interleukin 17 (IL-17)-mediated signaling and is recruited to the receptor for IL-17 after stimulation with IL-17. Here we found that Act1 was a 'client' protein of the molecular chaperone hsp90. The D10N variant of Act1 (Act1(D10N)) that is linked to susceptibility to psoriasis was defective in its interaction with hsp90, which resulted in a global loss of Act1 function. Act1-deficient mice modeled the mechanistic link between loss of Act1 function and susceptibility to psoriasis. Although Act1 was necessary for IL-17-mediated inflammation, Act1-deficient mice had a hyperactive response of the T H 17 subset of helper T cells and developed spontaneous IL-22-dependent skin inflammation. In the absence of IL-17 signaling, IL-22 was the main contributor to skin inflammation, which provides a molecular mechanism for the association of Act1(D10N) with psoriasis susceptibility.
Psoriasis is a chronic inflammatory disease of the skin that affects approximately 2% of the general population. The defining histological features of psoriatic skin lesions include epidermal hyperplasia, with aberrant differentiation and hyperproliferation of keratinocytes, as well as considerable infiltration of leukocytes into the dermis 1, 2 . Although psoriasis was initially classified as a disease mediated by the T helper type 1 (T H 1) response, published studies have highlighted a role for cells of the T H 17 subset of helper T cells and their cytokine network in propagating and amplifying skin inflammation 3 . T H 17 cells are a population of proinflammatory CD4 + effector T cells that are distinct from T H 1 and T helper type 2 (T H 2) cells because of their ability to produce interleukin 17A (IL-17A), IL-17F, IL-21 and IL- 22 (refs. 4-7) , all of which are greater in abundance in psoriatic lesions [8] [9] [10] .
Although IL-17 is required for host defense against extracellular microorganisms 11, 12 , it is also a critical mediator of the proinflammatory processes in various autoimmune and inflammatory disorders. The IL-17 signaling cascade requires a key signaling molecule, Act1 (also known as TRAF3IP2 or CIKS), to propagate downstream signaling events [13] [14] [15] . After stimulation with IL-17, Act1 is recruited to the receptor for IL-17 (IL-17R) through an interaction dependent on SEFIR-SEFIR domains ('similar expression to fibroblast growth factor-IL-17R'); this elicits Lys63-linked polyubiquitination of the ubiquitin ligase TRAF6, followed by the activation of the kinase TAK1 and the kinase IKK complex, which results in activation of the transcription factor NF-κB 16, 17 . Absence of Act1 leads to resistance to IL-17-mediated inflammation in mouse models of experimental autoimmune encephalomyelitis (EAE) and asthma 14, 18, 19 . Although Act1 is necessary for IL-17-mediated inflammatory responses, Act1-deficient mice (Traf3ip2 −/− mice; called 'Act1 −/− mice' here) develop spontaneous autoimmune diseases, including skin inflammation 20 , a phenotype also noted in mice with a spontaneous point mutation in Act1 that introduces an early stop codon 21 . Notably, three independent genome-wide association studies have linked a variant of Act1 with substitution of asparagine for the aspartic acid at position 10 (Act1(D10N)) to susceptibility to psoriasis [22] [23] [24] . However, questions about the effect of this variant on the function of Act1 and how this variant might predispose patients to psoriasis have remained unanswered.
One important goal of our study here was to investigate the effects of the D10N substitution on Act1 function. One possibility is that Act1(D10N) might somehow enhance IL-17 signaling and IL-17dependent effector function in skin inflammation. However, we found the opposite was true: Act1(D10N) was unable to interact with any of the known signaling components of the IL-17 pathway (including IL-17R, TRAF proteins and IKKi 25, 26 ) and resulted in abolished IL-17-dependent gene expression. We also found that the amino terminus of Act1 contains a highly conserved region necessary for the interaction of Act1 with the molecular chaperone hsp90. This is one of the most abundant cellular chaperones and has a crucial role in regulating a wide array of proteins essential for cell homeostasis 27, 28 . Substitutions that affect the amino terminus of Act1, such as D10N, lead to loss of regulation by hsp90 and, consequently, a 'dead' Act1 that is unable to propagate IL-17-mediated responses. Using Act1 −/− mice as a model for this 'dead' mutant, we found that the spontaneous skin inflammation was the result of the hyperactive T H 17 response of Act1 −/− mice, which suggested dysregulation of the immune system in the absence of functional Act1. In the absence of IL-17-signaling, IL-22 seemed to be the main contributor to skin inflammation, as neutralization of IL-22 resulted in alleviation of the inflammatory skin phenotype of Act1 −/− mice. Furthermore, we found that the hyperactive T H 17 response was T cell intrinsic, as mice with a T cellspecific deficiency in Act1 (Lck-Cre + Act1 fl/− mice) also developed a hyperactive T H 17 response. Consistent with that, Act1 −/− T cells transduced with a retroviral vector encoding Act1(D10N) had a more hyperactive T H 17 response than that of Act1 −/− T cells transduced with a retroviral vector encoding wild-type Act1, which indicated that the nonfunctional Act1(D10N) variant was associated with dysregulation of T cell function.
RESULTS

Act1 is a 'client' protein of hsp90
To search for Act1-interacting proteins, we treated HeLa human cervical cells and mouse embryonic fibroblasts (MEFs) with IL-17, then immunoprecipitated Act1 from lysates of those cells and analyzed the products by mass spectrometry. One protein in particular, hsp90, was repeatedly detected by mass spectrometry as an IL-17-induced, Act1interacting protein. We confirmed the interaction by coimmunoprecipitation and found that Act1 indeed interacted with hsp90 and that stimulation with IL-17 further promoted the interaction (Fig. 1a) .
The chaperone hsp90 is an ATPase that facilitates the folding and assembly of its 'client' proteins [29] [30] [31] [32] [33] [34] . Loss of the chaperone activity of hsp90 results in misfolding of client proteins, which leads to their degradation [29] [30] [31] . Thus, we used inhibitors of hsp90 to determine whether Act1 was an hsp90 client protein. Inhibitors of hsp90 such as geldanamycin (a natural hsp90 inhibitor) bind to the ATP-binding pocket at the amino terminus of hsp90 to inhibit ATP binding and the ATP-dependent hsp90 chaperone function 31 . The inhibitors 17-AAG (17-N-allylamino-17-demethoxygeldanamycin), a synthetic derivative of geldanamycin, and PU-H71, a purine scaffold inhibitor of hsp90, inhibit hsp90 through mechanisms similar to those used by geldanamycin 30, 34 .
Using the hsp90 inhibitors 17-AAG and PU-H71, we found a timedependent decrease in Act1 in MEFs and Hela cells ( Fig. 1b and data not shown). Using cycloheximide to block new protein translation, we found that geldanamycin accelerated the decay of Act1 (Fig. 1c) , which suggested that the stability of Act1 was dependent on hsp90. In addition, use of the proteasome inhibitor MG132 blocked the PU-H71-induced decay of Act1 (Fig. 1d) , which suggested that the degradation of Act1 after inhibition of hsp90 occurred via the proteasome. Consistent with reports suggesting that inhibitors of hsp90 lead to the dissociation of hsp90 from its client proteins 34 , we found that after treatment with PU-H71, Act1 dissociated from hsp90 within a short time period ( Fig. 1e ). Together these results demonstrated that Act1 was a client protein of hsp90.
The activity of hsp90 is required for IL-17 signaling Because Act1 is essential in IL-17-dependent signaling in autoimmune and inflammatory diseases 14, 15, 18, 19 , we sought to determine whether inhibition of hsp90 interfered with IL-17 signaling and IL-17-dependent gene expression. We pretreated MEFs for 1 h with inhibitors of hsp90 to disrupt the interaction of Act1 with hsp90 (with indiscernible Act1 degradation), followed by stimulation with IL-17. In the presence of the inhibitors, IL-17-dependent phosphorylation of the inhibitor IκBα and the kinases Erk and Jnk was almost completely abolished ( Fig. 2a,b ). After stimulation with IL-17, Act1 modifications (such as phosphorylation) help to govern specificity for downstream events 35, 36 . IL-17-induced modification of Act1 was considerably attenuated by inhibitors of hsp90 ( Fig. 2a,b , arrow), which indicated that Act1 was no longer recognized as a substrate of upstream kinases such as IKKi. Consistent with IL-17-induced signaling, the gene expression induced by IL-17 (IL-17A or IL-17F) was much lower after treatment with PU-H71 ( Fig. 2c,d) . To understand how the inhibitors of hsp90 blocked IL-17 signaling, we examined the effect of the inhibitors on the IL-17-mediated interaction of Act1 with other signaling components of the IL-17 pathway. Pretreatment with PU-H71 abolished the IL-17-dependent interaction of Act1 with TRAF6, TRAF3, TRAF2 and IKKi, as it also disrupted the interaction between Act1 and hsp90 ( Fig. 2e) . These results suggested that hsp90 activity had an essential role in the integrity of Act1 function. Inhibition of the A r t i c l e s npg A r t i c l e s chaperone function of hsp90 disrupted the interaction of Act1 with hsp90 and with other IL-17 signaling molecules, which resulted in the loss of IL-17-induced signaling and gene expression.
The main function of IL-17-induced Act1-mediated signaling is to coordinate local tissue inflammation via the upregulation of proinflammatory and neutrophil-mobilizing cytokines and chemokines. We next examined the effect of inhibiting hsp90 on IL-17-induced pulmonary inflammation in vivo. We pretreated wild-type mice for 2 d with the vehicle DMSO or with PU-H71, then injected recombinant IL-17 intranasally into the mice. At 24 h after IL-17 challenge, we analyzed cells in bronchoalveolar lavage fluid from the mice, as well as lung inflammation. Mice pretreated with PU-H71 and challenged with IL-17 had significantly fewer infiltrating cells, such as neutrophils, than did mice pretreated with DMSO and challenged with IL-17 (P < 0.05; Supplementary Fig. 1a ). The diminished inflammatory phenotype correlated with lower concentrations of CXCL1 (a potent neutrophil-recruiting chemokine) in the bronchoalveolar lavage fluid and lower Cxcl1 expression in the lungs ( Supplementary  Fig. 1b,c) . Furthermore, IL-17-induced expression of Csf2 (which encodes the cell-signaling molecule GM-CSF) and Il6 (which encodes IL-6) was also abolished in the lungs of mice pretreated with PU-H71 and challenged with IL-17, whereas it was present in mice pretreated with DMSO and challenged with IL-17 ( Supplementary Fig. 1b ). These results indicated the importance of hsp90 function in IL-17induced pulmonary inflammation.
Interaction of the Act1 amino terminus with hsp90
To determine the region(s) required for Act1 to interact with hsp90, we transfected HEK293 human embryonic kidney cells to express wild-type Act1 and truncation mutants of Act1, followed by immunoprecipitation and immunoblot analysis. This deletion analysis showed that deletion of amino acids 1-50 of Act1 resulted in loss of interaction with hsp90 ( Fig. 3a) . These results indicated that the amino terminus of Act1 was required for interaction with hsp90 ( Fig. 3b) . To further determine the minimum region sufficient for interaction with hsp90, we transfected HEK293 cells with constructs encoding partial regions of Act1 ( Supplementary Fig. 2 ). Our data indicated that the region of amino acids 1-100 of Act1 was sufficient for interaction with hsp90 ( Supplementary Fig. 2) . These findings suggested that the amino terminus of Act1 was necessary and sufficient for interaction with hsp90.
No interaction of Act1(D10N) with hsp90
We noted that the amino terminus of Act1 consists of a highly conserved motif ( Fig. 3c) . A genome-wide association study has identified . npg the psoriasis-susceptibility locus of Act1 (rs33980500) that encodes Act1(D10N) ( Fig. 3c) as the most significant associated singlenucleotide polymorphism of Act1 (P = 1.13 × 10 −20 ; odds ratio = 1.95) 24 . As the substitution in this Act1(D10N) variant is located in the amino terminus of Act1, we assessed the effect of the point substitution on the interaction of Act1 with hsp90. We transfected HEK293 cells to express wild-type Act1 and Act1(D10N), followed by immunoprecipitation and immunoblot analysis, and found that Act1(D10N) was unable to interact with hsp90 ( Fig. 3d) . This suggested that Asp10 had an essential role in the interaction of Act1 with hsp90.
It has been suggested that Act1(D10N) is defective mainly in its binding to TRAF6 (ref. 24) . We thus explored whether the interaction of Act1 with hsp90 was TRAF6 dependent. We identified two puta- 
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A r t i c l e s tive TRAF-binding sites in Act1 (residues 38-42 (TB1) and 333-337 (TB2)) 17 (Fig. 4a) . Alteration of both sites (Act1(TB1,TB2)) resulted in complete loss of the interaction between Act1 and TRAF2 and between Act1 and TRAF6 but had no effect on the interaction of Act1 with hsp90 ( Fig. 4b) . Furthermore, when we treated wild-type and Traf6 −/− MEFs with IL-17, followed by coimmunoprecipitation and immunoblot analysis, we found that Act1 from both wild-type and Traf6 −/− MEFs was able to interact with hsp90 ( Fig. 4c) , which indicated that the IL-17-induced hsp90 interaction was independent of TRAF6.
Notably, hsp90 functions as part of a chaperone machinery that guides the maturation or degradation of client proteins in two main forms of hsp90 complexes. Whereas the hsp90-Cdc37-p23 complex stabilizes the client protein, the hsp90-hsp70-HOP complex targets it for proteasomal degradation 34 . As the progression of the hsp90 complex toward the stabilizing form requires the binding and hydrolysis of ATP, inhibitors of hsp90 such as PU-H71 tend to drive the complex toward the proteasome-targeting form, which leads to more proteasomal degradation of the client protein 29 . Notably, we also repeatedly detected hsp70 by mass spectrometry as an IL-17-induced, Act1-interacting protein (data not shown), which suggested that Act1 may interact with the whole chaperone machinery in addition to interacting with hsp90. Therefore, we examined the interaction of wild-type Act1, Act1(D10N) and Act1(TB1,TB2) with co-chaperone proteins ( Fig. 4d-f) . Although IL-17 induced the interaction of wildtype Act1 and Act1(TB1,TB2) with hsp70, HOP and p23, there was no detectable interaction of Act1(D10N) with those co-chaperone proteins in response to stimulation with IL-17 ( Fig. 4e) . Consistent with those observations, treatment with PU-H71 led to the degradation of wild-type Act1 and Act1(TB1,TB2), but Act1(D10N) remained unaffected by this treatment (Fig. 4d) . We then examined the effect of PU-H71 on the interaction of Act1 with co-chaperone proteins. As expected, PU-H71 enhanced the interaction of wild-type Act1 and Act1(TB1,TB2) with hsp70 and HOP but diminished their interaction with hsp90 and p23 (Fig. 4f) . However, Act1(D10N) still failed to interact with the co-chaperone proteins in the presence of PU-H71 (Fig. 4f) . These observations indicated that Act1(D10N) failed to interact with hsp90 co-chaperone proteins, which rendered this Act1 variant resistant to hsp90-dependent regulation.
Act1(D10N) is a loss of function variant
Because the D10N substitution of Act1 resulted in loss of interaction with hsp90, we examined the effect of this substitution on IL-17 signaling. We reconstituted Act1 −/− MEFs with wild-type Act1, Act1(D10N) or vector DNA (Fig. 5a) . Re-expression of wild-type Act1 in Act1 −/− MEFs promoted IL-17-induced phosphorylation of the kinases Jnk and Erk as well as activation of NF-κB), but re-expression of Act1(D10N) did not (as shown by phosphorylation of IκBα, binding of DNA by NF-κB and NF-κB-dependent luciferase activity; (Fig. 5b-d) ).
Although IL-17 induced the interaction of wild-type Act1 with IL-17R, TRAF2, TRAF3, TRAF6 and IKKi, there was no detectable interaction of Act1(D10N) with these proteins in response to stimulation with IL-17 ( Fig. 5e) , which suggested Act1(D10N) was unable to interact with any of the proteins in the IL-17 signaling cascade known to interact with Act1. Notably, the D10N substitution also abolished the interaction of Act1 with the costimulatory molecule CD40 and the receptor for the B cell-activation factor BAFF ( Supplementary  Fig. 3 and data not shown). A published report has suggested that the amino terminus of Act1 contains a putative TRAF6-binding motif (PVEVDE; amino acids 6-11) 37 . A variant with substitution of the amino acids in that site to PVAVAA (Act1(T6BM)) did not interact with TRAF6. We found that the Act1(T6BM) mutant had the same mechanism of loss of function as Act1(D10N) ( Supplementary  Fig. 4) ; that is, impaired interaction with hsp90 and with the signaling components of the IL-17 pathway. Act1(D10N) was distinct from Act1(TB1,TB2), as Act1(TB1,TB2) still retained its interaction with hsp90, TRAF3 and IKKi, but Act1(D10N) did not ( Figs. 4b and 5e ). Moreover, in contrast to the results obtained with Act1(D10N), stimulation with IL-17 was able to induce modification on Act1(TB1,TB2) at amounts similar to those of wild-type Act1 (Fig. 4b, arrow) . Although the expression of Act1(D10N) was similar to that of wild-type Act1, IL-17 failed to induce modifications on Act1(D10N) (Fig. 5d, arrow) , a result also obtained with inhibition of hsp90 ( Fig. 2a,b) . Consistent with those observations, the expression of Il6, Cxcl1 and Csf2 induced by IL-17 alone or with IL-17 plus TNF was restored in Act1 −/− MEFs reconstituted with wild-type Act1 but not in those reconstituted with Act1(D10N) (Fig. 5f) . IL-17-induced gene expression was only partially lost in Act1 −/− MEFs reconstituted with Act1(TB1,TB2) ( Fig. 5f) .
These results suggested that whereas TB1 and TB2 were specific for TRAF6 binding and TRAF6-dependent IL-17 signaling, the D10N substitution probably perturbed the function of the amino-terminal region of Act1 critical for binding to hsp90, which resulted in the loss of a broader function of Act1 than TRAF6 binding. Furthermore, IL-17-mediated mRNA stability was not restored in MEFs reconstituted with Act1(D10N), whereas it was restored in MEFs reconstituted with wild-type Act1 (Supplementary Fig. 5 ). Collectively, these observations indicated that the D10N substitution might have caused a major conformational change in Act1 because of the absence of appropriate folding by hsp90, which resulted in the inability of Act1(D10N) to respond to and propagate IL-17-signaling events.
IL-22-mediated skin inflammation in Act1 −/− mice
Our results indicate that the loss of function of Act1(D10N) was due to the impaired regulation of Act1 by hsp90. Given that IL-17A is strongly linked to the pathogenesis of psoriasis, it was unexpected that this loss-of-function Act1 variant was associated with susceptibility to psoriasis. Although Act1 −/− mice are resistant to IL-17-dependent inflammation, such as EAE, they developed spontaneous autoimmune phenotypes, including skin inflammation 20 , characterized by epidermal hyperplasia and cell infiltration (Fig. 6) . Immunostaining showed that there were many more infiltrating CD3 + , CD4 + , CD11b + and Gr-1 + cells in Act1 −/− skin tissue than in wild-type tissue (Fig. 6a) , which indicated the participation of T cells, macrophages and neutrophils in the skin inflammation. Furthermore, we detected more IL-17 + and IL-22 + CD4 + T cells in Act1 −/− spleen and lymph nodes than in their wild-type counterparts ( Fig. 6b and Supplementary  Fig. 6) , and Act1 −/− skin had a greater abundance of transcripts encoding T H 17 cytokines (Il17a, Il17f and Il22) than did wild-type skin (Fig. 6d) . Analysis of cytokines in skin infiltrates also indicated more production of IL-17A and IL-22 by Act1 −/− skin than by wildtype skin, whereas IL-4, IL-6, TNF and IL-21 were undetectable (Fig. 6c and data not shown) . Unexpectedly, transcripts encoding IL-21 were undetectable in the lymph nodes and skin of Act1 −/− mice (data not shown). These results suggested that Act1 deficiency led to Given that IL-17A-IL-17F signaling was abrogated and IL-21 was undetectable in Act1 −/− mice, we hypothesized that IL-22 was the main contributor to skin inflammation. To test our hypothesis, we treated Act1 −/− mice with neutralizing antibody to IL-22 (anti-IL-22), followed by histopathology analysis. Treatment with that IL-22-neutralizing antibody resulted in less epidermal hyperplasia and infiltration of inflammatory cells in the skin than that in mice treated with isotype-matched control antibody (Fig. 6e) . Consistent with that histopathology analysis, treatment of Act1 −/− mice with the IL-22-neutralizing antibody resulted in much lower expression of Il17a, Il17f, Il22 and Il23 in the skin than that in mice treated with isotype-matched control antibody (Fig. 6f) . As cells of the immune response do not express the receptor for IL-22, IL-22 probably contributes to the inflammatory disease process via keratinocytes by inducing the expression of antimicrobial peptides and cytokines that amplify and maintain the proinflammatory environment needed to sustain T H 17 cells. Consistent with the literature 38, 39 , IL-22 was able to induce the expression of Il8 (which encodes IL-8), Defb1 (which encodes β-defensin), S100a8 (which encodes calgranulin A) and S100a9 (which encodes calgranulin B) in human keratinocytes ( Supplementary Fig. 7) . We indeed observed that neutralization of IL-22 resulted in much lower expression of Cxcl1, S100a8, S100a9 and Defb1 in the skin of Act1 −/− mice than in that of Act1 −/− mice treated with isotype-matched control antibody (Fig. 6f) . Together these results suggested that the T H 17 cell-derived cytokine IL-22 had a critical role in skin inflammation in Act1 −/− mice.
Like Act1 −/− mice, in which IL-17 signaling is abrogated, mice deficient in the IL-17 receptor IL-17RC (Il17rc −/− mice) also had a hyperactive T H 17 response. We detected more T H 17 cells in Il17rc −/− spleen and lymph nodes than in their wild-type counterparts ( Supplementary Fig. 8a and data not shown). Published EAE studies have shown that after immunization with the myelin oligodendrocyte glycoprotein epitope of amino acids 33-55, T cells from Il17rc −/− mice have a higher antigen-specific T H 17 cell response than that of their wild-type counterparts 40 . We found that Il17rc −/− mice also developed skin inflammation, as shown by epidermal hyperplasia and infiltration of T cells (Supplementary Fig. 8b) . Consistent with our histopathology analysis, we observed higher expression of Il17a, Il17f, Il22, S100a8, S100a9 and Defb1 in Il17rc −/− skin than in wildtype skin (Supplementary Fig. 8c) . We also detected more production of the T H 17 cytokines IL-17A and IL-22 by skin-infiltrating cells from Il17rc −/− mice than by those from their wild-type littermates (Supplementary Fig. 8d) . These results suggested that the impairment npg of IL-17-induced Act1-mediated signaling resulted in more T H 17 cells and IL-22-dependent skin inflammation in Act1 −/− mice. Indeed, neutralization of IL-22 in Il17rc −/− mice alleviated the inflammatory skin phenotype (Supplementary Fig. 8e,f) .
Act1(D10N) T cells have hyperactive T H 17 responses
To eliminate the hyperactive T H 17 response in Act1 −/− mice, we generated Act1 −/− mice also deficient in the receptor for IL-23 (Act1 −/− Il23r −/− mice) because it is well known that IL-23 has a critical role in the maintenance and population expansion of T H 17 cells 4, 6 . Act1 −/− Il23r −/− lymph nodes and skin had a lower abundance of T H 17 cells and transcripts of T H 17 cytokines (including IL-22) than did Act1 −/− lymph nodes and skin ( Fig. 7a and Supplementary  Fig. 9a ). Histopathology analysis showed less epidermal hyperplasia and infiltration by T cells in Act1 −/− Il23r −/− skin than in Act1 −/− skin (Fig. 7b) , which supported the proposal of a critical role for T H 17 cells in the skin inflammation of Act1 −/− mice. Consistent with that histopathology analysis, we observed lower expression of genes encoding T H 17 cytokines (Il17a, Il17f and Il22), as well as of S100a8, S100a9 and Defb1, in Act1 −/− Il23r −/− skin than in Act1 −/− skin (Fig. 7c) . A published study has reported that the spontaneous point mutation that introduces a premature stop codon in Act1 leads to spontaneous skin inflammation with a greater abundance of transcripts encoding T H 17 cytokines in the mutant mice 21 . Similarly, hyperproduction of immunoglobulin E (IgE) has been observed in Act1 −/− mice and has been attributed to the loss of negative regulation in B cells 20 . We found that hyperproduction of IgE was also reversed in Act1 −/− Il23r −/− mice (Supplementary Fig. 9b ), which suggested a link between the hyperactive T H 17 response and hyperproduction of IgE in these mice.
Next we sought to determine the cell type responsible for the hyperactive T H 17 response noted above. Using mice with T cell-specific deficiency in Act1 (Lck-Cre + Act1 fl/− mice), we examined the contribution of T cells to this phenotype. We observed inflammation, along with infiltrates of CD4 + , CD8 + and CD11b + cells, in the skin of Lck-Cre + Act1 fl/− mice but not in the skin of their Act1-sufficient Lck-Cre + Act1 fl/+ littermates ( Fig. 8a) . Furthermore, skin infiltrates isolated from Lck-Cre + Act1 fl/− mice produced more IL-17A and IL-22 than did those from Lck-Cre + Act1 fl/+ mice (Fig. 8b) . When we polarized naive T cells into T H 17 cells ex vivo, Lck-Cre + Act1 fl/− T cell samples included more IL-17 + CD4 + T cells than did Lck-Cre + Act1 fl/+ T cell samples (Fig. 8c) , which indicated a critical role for Act1 in modulating T H 17 polarization. Consistent with that, we detected higher expression of Il17a and Il22 in Lck-Cre + Act1 fl/− T H 17 cells and more IL-17 and IL-22 in culture supernatants of Lck-Cre + Act1 fl/− T H 17 cells than in their Lck-Cre + Act1 fl/+ counterparts (Fig. 8d) . To determine whether the D10N substitution in T cells was sufficient for the hyperactive T H 17 response, we transduced Act1 −/− T cells with retrovirus containing vector encoding green fluorescent protein (GFP) alone or retrovirus containing vector encoding GFP and wild-type Act1 or Act1(D10N) and polarized the T cells under T H 17-skewing conditions. We sorted GFP + cells for RT-PCR analysis of Il17a and Il22. Act1 −/− T cells transduced with retroviral vector encoding Act1(D10N) had a more hyperactive T H 17 response than that of Act1 −/− T cells transduced with retroviral vector encoding wild-type Act1 (Fig. 8e) . Furthermore, when we injected Act1 −/− T cells transduced as described above into mice deficient in recombinationactivating gene 1 (Rag1 −/− mice) and examined the lymph nodes and spleens of the recipient Rag1 −/− mice 2 weeks later, we observed that Act1(D10N) conferred a hyperactive T H 17 response (Fig. 8f,g) . Together these results suggested that the nonfunctional Act1(D10N) variant was associated with the dysregulation of T cell function.
DISCUSSION
In this study, we found that although Act1 was necessary for IL-17mediated inflammatory responses, Act1 −/− mice had a hyperactive T H 17 response and developed spontaneous skin inflammation, which was attenuated by neutralization of IL-22. These results demonstrated that in the absence of IL-17-Act1 signaling, the consequent hyperactive T H 17 response was biased toward IL-22, which acted as the main contributor of skin inflammation. Given the critical role of IL-22 in human psoriasis, this mouse model provides a plausible interpretation for how the Act1(D10N) variant is linked to susceptibility to psoriasis. We found that Act1 was a client protein of the molecular chaperone hsp90. The Act1(D10N) variant was defective in its interaction with hsp90, which resulted in a complete loss of function of Act1. Notably, Act1 −/− T cells restored with the Act1(D10N) variant had a hyperactive T H 17 phenotype, but those restored with the wild-type Act1 did not, which demonstrated that the nonfunctional Act1 was associated with a dysregulation of T cell function, a risk factor for autoimmune diseases, including psoriasis 1, 2, 41 .
The D10N substitution is in a highly conserved motif at the amino terminus of Act1, which contains an hsp90-binding region that when altered, as in Act1(D10N) and Act1(T6BM), led to a broad loss of function of Act1 and, consequently, defective IL-17 signaling. The loss of Act1 modifications during the use of inhibitors of hsp90 indicated that the chaperone activity of hsp90 (and thus proper folding of Act1) was critical for the recruitment of Act1 to the IL-17 receptor complex and for its recognition as a substrate of upstream kinases during IL-17 signaling. Mutations that affect the ability of Act1 to bind to hsp90, such as those that produce the Act1(D10N) and Act1(T6BM) variants, most probably result in major structural and conformational changes in Act1 that abolish IL-17-mediated signaling. Notably, we also observed that the interaction between Act1 and hsp90 was enhanced by stimulation with IL-17, which suggested that in addition to its chaperone function, hsp90 may act as a scaffolding protein in the IL-17 signaling pathway. Further evaluation is needed to delineate the possible role of hsp90 in the signaling cascade.
Because IL-17A is strongly linked to the pathogenesis of psoriasis, it seems contradictory that the loss of function of Act1(D10N) and consequent impaired IL-17 signaling would be linked to greater susceptibility to psoriasis. As the D10N substitution rendered Act1 nonfunctional, we attempted to use the Act1 −/− mice to model the in vivo effect of this 'dead' mutant. Notably, although Act1 −/− mice were defective in IL-17-mediated signaling, IL-22 functioned as the main participant in the pathogenesis of skin inflammation in Act1 −/− mice. In the normal state, IL-22 acts as a skin-repair agent, inducing keratinocyte proliferation and maintaining barrier integrity. In the pathogenic state, enhanced and dysregulated production of IL-22 leads to the hyperproliferation and aberrant differentiation of keratinocytes 8 . In mouse models of psoriasis, including the data we have presented here, skin inflammation can be attenuated by IL-22 neutralization [42] [43] [44] . A greater abundance of IL-22 protein and Il22 transcripts are also found in the serum and skin lesions of patients with psoriasis 9 . It is possible that in patients with psoriasis who express Act1 variant(s), the pathogenesis of the disease is mediated by IL-22, which compensates for the loss of IL-17 signaling. Thus, such findings may suggest an individualized therapeutic approach for patients with the Act1(D10N) variant. At present, no animal model has been able to mimic all the characteristics of human psoriasis. However, given the association of Act1(D10N) with the susceptibility of humans to psoriasis, our findings of complete loss of function of Act1(D10N) and the skin inflammation in Act1 −/− mice emphasize a possible mechanistic npg link between the skin inflammation of Act1 −/− mice and the pathogenesis of psoriasis in patients with the Act1(D10N) variant.
Notably, in an IL-23-induced skin inflammation model of psoriasis, injection of IL-23 leads to a greater abundance of Il22 transcripts in the skin of the Il17a −/− mice than in that of wild-type mice 45 . Such findings suggest that loss of IL-17 signaling may result in a hyperactive T H 17 response, which would indicate a negative regulatory role for IL-17 signaling in T H 17 polarization in vivo. Additional studies are needed to elucidate details of the molecular mechanism by which IL-17 signaling may modulate the T H 17 response. We note that even though they have a larger T H 17 cell population, Il17rc −/− mice and Act1 −/− mice remain resistant to the pathogenesis of IL-17-dependent diseases such as EAE 14, 18, 40 . Those data and the results we have presented here collectively suggest that T H 17-mediated diseases are cytokine specific: although IL-17 has the dominant role in T H 17mediated EAE, IL-22 is responsible for the T H 17-mediated skin inflammation in Act1 −/− and Il17rc −/− mice.
We demonstrated that the hyperactive T H 17 response in Act1 −/− mice was T cell intrinsic, as we also observed the skin inflammation and hyperactive T H 17 response in Lck-Cre + Act1 fl/− mice. Furthermore, Act1 −/− T cells reconstituted with Act1(D10N) showed a hyperactive T H 17 response, whereas cells reconstituted with wild-type Act1 did not, which indicated that the D10N substitution of Act1 and its loss of function was sufficient to cause the hyperactive T H 17 phenotype. Our data obtained with Il17rc −/− mice indicated possible negative feedback of IL-17 signaling on T H 17 cells. However, as Act1 also functions under signaling mediated by other members of the IL-17 family, future studies should determine whether T cell-specific deletion of IL-17RC in mice also results in a hyperactive T H 17 response.
The enhancement in T H 17 cells, cytokine transcripts and skin inflammation in Act1 −/− mice was reversed in Act1 −/− Il23r −/− mice, which further supported the proposal of a critical role for T H 17 cells in the skin inflammation of Act1 −/− mice. We also found that the hyperproduction of IgE of Act1 −/− mice was reversed in Act1 −/− Il23r −/− mice, which suggested a causal link between the hyperactive T H 17 response and the hyperproduction of IgE in these mice. Although serum IgE concentrations are not among the common diagnostic tests for psoriasis, nor have serum IgE concentrations been well documented in patients with psoriasis, higher concentrations of IgE have been reported in a cohort of patients with psoriatic erythroderma, a severe type of psoriasis 46 . Serum IgE concentrations were higher in 81.3% of a group of patients with psoriatic erythroderma, compared with 6.3% of the control group. In addition, case studies involving psoriasiform lesions and higher IgE concentrations have been similarly documented 47, 48 . It would thus be useful to study IgE concentrations in patients with the Act1(D10N) variant to determine whether this substitution defines a specific cohort of patients with psoriasis.
In addition to its role as a component in the IL-17R signaling cascade in fibroblasts, endothelial cells, epithelial cells, astrocytes and macrophages, Act1 has a negative role in the CD40-CD40 ligand and BAFF-BAFF receptor signaling pathways in B cells that control the maturation and survival, respectively, of B cells 20 . Loss of Act1 thus results in more B cells, which culminates in splenomegaly, lymphadenopathy, hypergammaglobulinemia and autoantibody production. The D10N substitution also abolished the interaction of Act1 with CD40 and the receptor for BAFF. Therefore, it is possible that the loss of negative regulation of B cell function in Act1 −/− mice might also contribute to the pathogenesis of the skin inflammation in mice and possibly in patients with the D10N substitution. However, we have found that Act1 −/− mice that are also deficient in the immunoglobulin µ-chain still developed antigen-specific hyperactive T H 17 responses after immunization with the myelin oligodendrocyte glycoprotein epitope of amino acids 33-55 and had more T H 17 cells in their spleen and lymph nodes than did mice deficient only in the immunoglobulin µ-chain (X.L., data not shown), which suggested that the hyperactive T H 17 response in Act1 −/− mice was most probably independent of B cells. Nevertheless, future studies should determine whether patients with psoriasis who express the Act1(D10N) variant have other autoimmune comorbidities.
METHODS
Methods and any associated references are available in the online version of the paper.
